Nanobiotix Presents Results of NBTXR3 (PEP503) in P-Ib/II Study for Rectal Cancer at ASCO-GI 2021
Depomed changes name to Assertio Therapeutics
Depomed changes name to Assertio Therapeutics
Shots:
- Depomed changes name to Assertio Therapeutics on Aug 15, 2018, with a strategic focus on our neurology, orphan and specialty medicines
- The rebranding is done after Senate committee opened probe for opioid marketing last year
- Assertio’s common stock has started trading with new ticker “ASRT” from Aug 15, 2018. Depomed also completed the relocation of headquarters from Newark to Lake Forest
